6315—S (Flomoxef) in respiratory tract infections

Kohtaro Oizumi, Akira Watanabe, Seiichi Aonuma, Kiyoshi Konno, Akira Saito, Fumio Nagahama, Kazuo Takebe, Masao Tamura, Izumi Hayasi, Hazime Watanabe, Jyutaroh Sihmomura, Akira Ujiie, Isao Takahori, Yohmei Hiraga, Kohki Kikuchi, Rensuke Kuroda, Kyuiciuroh Sekine, Hiroshi Takagi, Mikiiiiko Tango, Morikuni AbeIkuko Yamagishi, Choei Itoh, Keisuke Takeuchi, Osamu Yajima, Kiyoshi Kawamorita, Kikuo Ohnuma, Tukasa Yoshida, Kazuo Mizukosiii, Masayuki Yosiiizawa, Sauukoh Shindom, Kazuo Satom, Kohsaku Nagai, Tekuo Hasuike, Eijyu Umehara, Yasuo Sugawara, Moriaki Nishina, Shigemi Kohsaka, Shigeo Takizawa, Yuzuru Matsumoto, Kenkichi Shikanai

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Clinical efficacy, bacteriological effects and safety of the parenteral oxacephem antibiotic 6315-S (Flomoxef) in treatment of respiratory infections were evaluated. In 78 patients (with acute bronchitis, 1; acute exacerbation of chronic bronchitis, 6; bacterial pneumonia, 56; bronchial pneumonia, 3; secondary infection in chronic respiratory disease, 7; pulmonary suppuration, 2; and other respiratory infections, 3) 6315-S was markedly effective in 15, effective in 42, slightly effective in 13 and ineffective in 8 patients. The efficacy rate was 73.1%. Fourteen cases (e. g., mycoplasma pneumoniae) were excluded as unevaluable. As causative organisms, 30 strains were detected: S. pneumoniae, 7; S. aureus, 5; Klebsiella spp., 4; Haemophilus influenzae, 4; and 10 other strains. Of 23 strains which could be evaluated bacteriologically, 17 were eliminated by administration of 6315-S. As regards safety, out of 92 patients treated, three developed allergic symptoms, such as exanthema, and one patient gastrointestinal symptoms. Thus frequency of side-effects was 4.4% (4/92). Abnormal laboratory values were found in 17 cases (18.5%): abnormal liver fuction test, 11, eosinophilia, 4; abnormal liver function with eosinophilia, 1; prolonged prothrombin time, 1. None of these changes was serious, all values having normalized soon after cessation of treatment.

    Original languageEnglish
    Pages (from-to)541-561
    Number of pages21
    JournalChemotherapy
    Volume35
    DOIs
    Publication statusPublished - 1987

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of '6315—S (Flomoxef) in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this